KEYNOTE-180

NCT02559687 📎

Regimen

Experimental
pembrolizumab

Population

Advanced esophageal cancer (ESCC or adenocarcinoma/GEJ) progressed after >=2 prior systemic therapies

Key finding

ORR 9.9% all (95% CI 5.2-16.7); ESCC 14.3%; CPS>=10 13.8%; durable responses >12 mo; safety acceptable

Source: PMID 30570649

Timeline

    Guideline citations

    • NCCN ESOPHAGEAL (p.121)